Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2025-05-12 Earnings Release
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest confirms Guidance for 2025
Earnings Release Classification · 100% confidence The document is a press release dated May 12, 2025, detailing the financial results for the first quarter of fiscal year 2025 (Sales, EBIT, Earnings after taxes). It explicitly mentions 'Quarterly / Interim Statement' in the keywords and provides detailed financial figures for a period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it contains earnings highlights, the depth of the financial detail and the confirmation of guidance suggest it is more than just a brief Earnings Release (ER). It is not an announcement of a report (RPA) as it contains the substance of the results. Q1 2025
2025-05-12 English
Q1 statement / Q1 financial report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 31 March 2025. It contains detailed financial performance data, including consolidated statements of income, financial position, and cash flow, as well as management's analysis of business performance, research and development, and financial position. It is a comprehensive interim report rather than a mere announcement or summary, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-12 English
Bericht zur Gleichstellung und Entgeltgleichheit nach EntgTranspG als Anlage des Lageberichts zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Remuneration Information Classification · 99% confidence The document is titled "Bericht zur Gleichstellung und Entgeltgleichheit nach EntgTranspG als Anlage des Lageberichts zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022" (Report on Equality and Pay Equity according to EntgTranspG as an appendix to the Management Report for the fiscal year from 01.01.2022 to 31.12.2022). It explicitly discusses compliance with § 21 of the German Pay Transparency Act (EntgTranspG) and details measures taken regarding gender equality and equal pay. Although it is an appendix to the Management Report (Lagebericht), the content itself is a specific regulatory disclosure focused on social/governance aspects (equality/pay equity). This type of specific, non-financial, non-audit report focusing on ESG-related governance metrics aligns best with the Environmental & Social Information (SR) category, as it details social performance metrics, even though it is mandated by German corporate law and attached to the annual filing structure. It is not a full 10-K, nor is it a general Audit Report (AR). It is a specific social/governance report.
2025-05-05 German
Berichtigt am 17.06.2025
Annual Report Classification · 95% confidence The document text contains detailed financial and operational information about the Biotest Group for the fiscal year 2024, including business model, strategy, economic environment, risk and opportunity reports, and segment reporting. It references consolidated financial data, IFRS standards, and includes a comprehensive management discussion of business activities and outlook. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content aligns with what is typically found in an Annual Report (10-K equivalent) or a Management Discussion and Analysis (MDA). However, the presence of detailed financial data, segment information, and comprehensive business review strongly supports classification as an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the document is best classified as an Annual Report (10-K). FY 2024
2025-04-16 German
Biotest AG increases sales by 6% in financial year 2024
Earnings Release Classification · 100% confidence The document is a press release dated March 31, 2025, summarizing the financial performance for the 'financial year 2024'. It provides key figures like sales (€726.2 million), EBIT (€94.5 million), and outlook for 2025. Crucially, the text explicitly states: 'The 2024 Annual Report is available on the company’s website.' This indicates the document itself is an announcement summarizing the results, not the full, comprehensive Annual Report (10-K). Since it contains the primary financial highlights and results summary, it fits the definition of an Earnings Release (ER). While it discusses the full year, the format is a press release announcing results, which aligns best with ER, rather than the comprehensive 10-K filing itself. It is not a Report Publication Announcement (RPA) because it contains substantial financial data, not just a notice that a report is available. FY 2024
2025-03-31 English
Annual financial report 2024
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2024' and contains comprehensive financial data, key figures, a foreword from the Chairman, and a detailed 'Combined Group Management Report'. It covers the full fiscal year 2024, providing a complete overview of the company's performance, strategy, and financial position, which aligns perfectly with the definition of an Annual Report (10-K). FY 2024
2025-03-31 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.